In one series of 12 patients diagnosed with NF2 before 18 years old, there was a high tumor burden with >75% of patients having VS, other cranial nerve schwannomas, meningiomas or spinal cord tumors [Nunes and MacCollin, 2003]

In one series of 12 patients diagnosed with NF2 before 18 years old, there was a high tumor burden with >75% of patients having VS, other cranial nerve schwannomas, meningiomas or spinal cord tumors [Nunes and MacCollin, 2003]. Marco Giovannini(House Research Institute)to review the state of NF2 treatment and clinical trials. This manuscript summarizes the expert opinions about current treatments for NF2 associated tumors and recommendations for advancing therapies emerging from that meeting. The PF-06821497 development of effective therapies for NF2 associated tumors has the potential for significant clinical advancement not only for patients with NF2 but for thousands of neuro-oncology patients afflicted with these tumors. Keywords:Neurofibromatosis type 2, meningioma, schwannoma, vestibular schwannoma, ependymoma, radiotherapy, molecular therapy, surgery == INTRODUCTION == Neurofibromatosis type 2 (NF2) is an autosomal dominant tumor suppressor disorder that causes multiple tumor types to form at every level of the nervous system. Although a rare disorder (estimated 1 in 2533,000 births) [Evans PF-06821497 et al., 2005;Evans et al., 2010], the tumor types seen in NF2 are among the most common in neuro-oncology (Fig 1). The hallmark of NF2 Rabbit polyclonal to MTOR is bilateral vestibular schwannomas (VS) which progressively enlarge leading to PF-06821497 sensorineural hearing loss and deafness [Evans, 2009]. VS may also cause brainstem compression resulting in severe neurologic morbidity and mortality. Half of all individuals with NF2 will also develop intracranial meningiomas and 75% will develop spinal tumors including schwannomas, meningiomas and ependymomas [Evans, 2009]. The vast majority of individuals with NF2 require surgery, and most will have multiple procedures during their lifetime. The progression of NF2 and requisite surgical intervention can result in deafness, facial palsy, blindness, seizures and hemiparesis. == Figure 1. == The tumors that are found in NF2 (schwannomas, meningiomas and ependymomas) are some of the most common seen in neuro-oncology overall. Until recently there were few therapeutic options for individuals with NF2. Thankfully things have progressed with increasing understanding of the genetic basis of NF2, as well as, emerging molecular parallels within various cancers for which drug therapies are in development or already clinically available. However challenges lay ahead for the NF2 community, including prioritizing candidate drugs, controlling individual PF-06821497 recruitment to medical tests and integrating fresh therapies into medical care and attention across multiple medical and medical disciplines. This short article summarizes the latest recommendations for NF2 medical management; improvements in understanding the molecular underpinnings of this disorder; and progress made to day in implementing NF2 medical tests. == CURRENT CLINICAL CARE Requirements FOR NF2 == == Medical Management of NF2 Vestibular Schwannoma == Idiopathic VS are fairly common, with roughly 3,000 new instances per year in the United States, with growing incidence in recent years [Evans et al., 2005]. These tumors cause unilateral hearing loss, tinnitus, and imbalance. The primary treatment modality for these tumors is definitely medical resection or progressively, radiosurgery, especially for tumors <3cm [Rowe et al., 2003]. NF2 VS do not behave exactly like sporadic VS and require special thought [Samii et al., 1997]. Care team experience is definitely important in the formulation of a treatment plan for NF2 connected VS which generally includes observation, surgery, stereotactic radiation or increasingly, drug therapy. The 1st important therapeutic thought for NF2 connected VS is the presence brainstem compression. Large bilateral VS with obstructive hydrocephalus may cause rapid loss of consciousness, herniation and death. In such cases urgent surgical removal of at least one VS is the 1st life-preserving priority along with diverting cerebrospinal fluid via shunt to address the hydrocephalus. For tumors greater than or equal to 3 cm in diameter but no evidence of hydrocephalus or brainstem compression, medical resection should be considered as 1st line therapy, PF-06821497 providing thought to brainstem safety and facial nerve preservation [Anderson et al, 2005;Myrseth et al., 2009;Wiegand et al., 1996]. The various available methods for VS surgery (translabyrinthine, middle cranial fossa and suboccipital) each offers advantages and disadvantages; but ultimately medical outcome is highly dependent on the teams experience overall and with the particular approach [Bennet and Hayes, 2007;Thomsen et al., 1994;Welling et al., 1999]. The primary advantage of the translabyrinthine approach is direct access to the tumor where it comes into contact with the facial nerve, allowing development of a clean dissection aircraft between facial nerve and.